Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 13/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263796 | 0.92 | EGFR (0.39) | KDM4EMAPK1ALDH1A1KDR | |
| SCHEMBL2002754 | 0.85 | KDM4E (0.46) | KDM4EMAPK1ALDH1A1KDRHPGD | |
| SCHEMBL4376396 | 0.84 | PDE3B (0.40) | KDM4EMAPK1ALDH1A1HSD17B10HPGD | |
| SCHEMBL4377096 | 0.84 | KDM4E (0.38) | KDM4EMAPK1ALDH1A1HSD17B10HPGD | |
| SCHEMBL3329620 | 0.84 | PDE3B (0.40) | KDM4EMAPK1ALDH1A1HSD17B10HPGD | |
| SCHEMBL4375766 | 0.83 | PDE3B (0.39) | KDM4EMAPK1ALDH1A1HSD17B10HPGD | |
| SCHEMBL4297391 | 0.83 | PRKAB2 (0.42) | KDM4EMAPK1ALDH1A1KDRHPGD | |
| SCHEMBL1806456 | 0.82 | PDE3B (0.47) | KDM4EMAPK1ALDH1A1HSD17B10HPGD | |
| SCHEMBL4380700 | 0.80 | SRC (0.49) | KDR | |
| SCHEMBL1507501 | 0.78 | PDE3B (0.43) | KDM4EMAPK1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1005470-B1 | OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2007-08-01 | — | — | EP | disclosed |
| US-6294532-B1 | TREATMENT OF A NUMBER OF DISEASE STATES INCLUDING CANCER AND RHEUMATOID ARTHRITIS. | ZENECA LIMITED (GB) | 2001-09-25 | — | — | US | disclosed |
| EP-1005470-A1 | OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ZENECA LIMITED (GB) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999010349-A1 | OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ZENECA LIMITED (GB) | 1999-03-04 | — | — | WO | disclosed |